Full Press Release Details
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to three individuals whose grant date was in either September 2026 or October 2026. The grants, in the form of Restricted Stock Units (RSUs), totaled 21,2